Record Oncology Revenue
Champions Oncology Reports Record $59 Million Revenue, Driving Strategic Investments
Anonymous
Key Points
1
Champions' fiscal-year 2026 MD&A describes its in vivo oncology studies leveraging TumorBank-derived tumors implanted in mice, paired with pharmacology, biomarker and data platforms to predict therapy efficacy and identify patient populations and biomarker targets.
2
Champions generated positive Adjusted EBITDA in every quarter of fiscal 2026, reflecting ongoing cost discipline even as it invests in radiopharmaceuticals, data platforms, Corellia technology, and commercial expansion.
3
Fourth-quarter 2026 revenue reached $13.8 million, up 12% from $12.4 million in the prior-year quarter.
4
FY2026 revenue rose about 4% year over year, helped by a stronger core research services business, offsetting the absence of a prior year's roughly $4.5 million data-licensing transaction.
5
Radiopharmaceutical investments continue, with certain radiopharmacology activities moved in-house, temporarily increasing outsourced costs during capability build-out.
Champions Oncology posted record fiscal 2026 oncology revenue of $59.4 million, up about 4% from the prior year, while delivering positive adjusted EBITDA in every quarter of the year, according to Yahoo Finance. The full-year adjusted EBITDA totaled $1.6 million, even as the company absorbed heavy investments in radiopharmaceuticals and new technology platforms.
The results come despite a net loss of $1.18 million for the year — a sharp swing from net income of $4.7 million in fiscal 2025, according to Market Screener. The prior year benefited from a one-time $4.5 million data-licensing deal that did not repeat in 2026.
Record Fourth Quarter Caps a Strong Year
Champions closed fiscal 2026 with a strong fourth quarter. Q4 revenue hit $13.8 million, up 12% from $12.4 million in the same quarter a year ago, according to Yahoo Finance. Gross margin for oncology services reached 51% in the quarter. For the full year, that margin was about 48%.
Fourth-quarter adjusted EBITDA came in at $158,000. The company ended the year with $4.9 million in cash and no debt, according to Market Screener. That gives Champions a clean balance sheet as it funds new growth initiatives heading into fiscal 2027.
How Champions' Core Research Business Actually Works
Champions runs what it calls Translational Oncology Solutions. The company takes tumors from its TumorBank library and implants them in mice. Scientists then test cancer drugs on those tumors. This helps drug makers predict which therapies will work — and for which patients — before human trials begin, according to Champions' annual 10-K filing reviewed by Market Screener.
The company pairs that biology work with pharmacology tools, biomarker analysis, and a data platform. This combination helps clients identify the right patient groups for their drugs. Champions calls this its core research services business, and management says it strengthened meaningfully in fiscal 2026, according to Yahoo Finance.
Radiopharmaceutical Push Adds Costs but Signals Big Ambition
Champions is making a serious bet on radiopharmaceuticals — cancer treatments that use radioactive molecules to target tumors. The company moved some of this work in-house during fiscal 2026. That temporarily raised outsourced costs as Champions built out the capability, according to Seeking Alpha.
The company also continued building out its Corellia technology platform. Seeking Alpha reported that Corellia is now fully funded heading into fiscal 2027. Management framed these investments as key drivers of future revenue, even though they weighed on margins in the near term.
Fiscal 2027 Outlook Hinges on Cost Discipline and New Revenue Streams
Champions said it will keep pursuing cost discipline while expanding commercially. The goal is to grow revenue from both its core oncology research business and newer platforms like radiopharmaceuticals and Corellia, according to Yahoo Finance. Management pointed to a stronger research pipeline as evidence the strategy is working.
The absence of a big one-time data deal — like the $4.5 million transaction that boosted fiscal 2025 — means Champions must grow organically to move the needle. Hitting positive adjusted EBITDA in all four quarters of 2026 suggests the company has a stable enough cost base to do that, according to Seeking Alpha.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
11
Articles
45
Reach
56
A
AnonymousAuthor
